FibroGen, Inc
10.91+0.10 (+0.93%)
Oct 29, 4:00:02 PM EDT · NasdaqGS · FGEN · USD
Key Stats
Market Cap
44.12MP/E (TTM)
-Basic EPS (TTM)
-21.61Dividend Yield
0%Recent Filings
8-K
FibroGen sells China unit to AstraZeneca
FibroGen closed the sale of its China subsidiary, FibroGen International (Hong Kong) Ltd., to AstraZeneca on August 29, 2025, for approximately $220 million, including $85 million in enterprise value and $135 million in net cash. The deal triggered repayment of an $81 million senior secured term loan to Morgan Stanley, bolstering the balance sheet with a pro forma cash position of $145 million as of June 30, 2025. This divestiture sharpens focus on core operations. Yet, it incurs a $6.8 million debt extinguishment loss.
8-K
FibroGen sells China unit
FibroGen completed the sale of its China subsidiary to AstraZeneca on August 29, 2025, for $220 million, including $85 million enterprise value and $135 million net cash, while repaying an $81 million term loan to Morgan Stanley funds. This bolsters the balance sheet and extends cash runway into 2028. The company retains roxadustat rights outside China and South Korea. Phase 2 trial of FG-3246 starts soon.
8-K
China approval for FibroGen sale
FibroGen secured China regulatory approval on August 18, 2025, for selling its China operations—including roxadustat assets—to AstraZeneca, under their February 20, 2025 agreement. The deal, with AstraZeneca as the long-time partner, stays on track to close in Q3 2025, subject to standard conditions. FibroGen keeps roxadustat rights outside China and select markets. Closing hinges on final deliverables.
8-K
FibroGen eases cash covenant
FibroGen signed its fourth amendment to the April 2023 financing agreement with Morgan Stanley-managed lenders on August 12, 2025, easing liquidity rules by dropping the minimum qualified cash requirement from $18.75 million to $15 million in U.S. accounts. This tweak, effective immediately, grants the biotech more operational breathing room amid ongoing covenant adjustments. Lenders hold firm on other terms. No new waivers or risks disclosed.
8-K
China sale upsized to $210M
FibroGen boosted its China sale to AstraZeneca to $210 million total consideration, including $125 million in net cash, with closure eyed for Q3 2025. This extends the cash runway into 2028 while repaying the Morgan Stanley loan. Pipeline advances include FG-3246's Phase 2 mCRPC trial starting Q3 and FDA-aligned Phase 3 for roxadustat in LR-MDS anemia, protocol filing Q4. Q2 revenue hit $1.3 million, narrowing continuing operations loss to $13.7 million. Sale proceeds fuel key trials.
AKRO
Akero Therapeutics, Inc.
54.00+0.00
ATXS
Astria Therapeutics, Inc.
12.60+0.13
DSGN
Design Therapeutics, Inc.
6.49-0.19
FBLG
FibroBiologics, Inc.
0.39-0.03
GYRE
Gyre Therapeutics, Inc.
7.54-0.20
IBRX
ImmunityBio, Inc.
2.42-0.16
INBX
Inhibrx Biosciences, Inc.
77.05+8.56
KROS
Keros Therapeutics, Inc.
15.04-0.14
MGNX
MacroGenics, Inc.
1.69-0.16
XBIT
XBiotech Inc.
2.37-0.02